川芎嗪联合尿激酶静脉溶栓治疗急性心肌梗死的临床研究

目的观察川芎嗪联合尿激酶静脉溶栓治疗急性心肌梗死（AMI）的效果,探索基层医院提高AMI治疗效果的新途径。方法将495例符合静脉溶栓标准的AMI患者随机分为对照组和治疗组,两组的尿激酶溶栓和常规治疗相同,治疗组在此基础上加用川芎嗪,120mg/次,每天1次。观察两组患者的再通率、再灌注心律失常发生率、心功能、并发症、住院死亡率等。结果治疗组和对照组再通率分别为61．8％、60．1％,两组比较差异无统计学意义（P〉0．05）。再灌注心律失常的发生率治疗组和对照组分别为53．2％和71．3％,差异有统计学意义（P〈0．01）。静脉溶栓后两组患者心功能、并发症、住院死亡率等方面差异无统计学意义（P〉0．05）。结论尿激酶静脉溶栓联合川芎嗪治疗AMI能有效抑制溶栓后再灌注心律失常的发生,对心功能降低的抑制作用近期不明显。

Clinical observation on effect of intravenous thrombolytic treatment for acute myocardial infarction patients with Ligustrazine and Urokinase

Objective To observe the effect of Ligustrazine(LT) and Urokinase in intravenous thrombolytic treatment of acute myocardial infarction(AMI),and explore a new way of improving the therapeutic effect of AMI in basic hospital.Methods Four hundred and ninety five patients with AMI(who were conform to the standard of intravenous thrombolysis therapies) were randomly divided into two groups: control group and observation group.The patients in both groups received Urokinase intravenous thrombolysis therapy and rou...